INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Narrative review / 2024

Approved obesity medications added to lifestyle interventions improve long-term weight loss and cardiometabolic risk factors over lifestyle interventions alone.

This narrative review synthesized data on the efficacy and safety of medications approved for long-term obesity management. Compared with lifestyle interventions alone, all approved obesity medications were more effective for long-term weight loss and cardiometabolic improvements. Older medications were associated with mean weight losses of 5-10%, while newer incretin analogues (semaglutide and tirzepatide) were linked to sustained mean reductions of 15-20%. The review notes challenges including cost, availability, weight regain, and loss of lean muscle and bone mineral density.

Study type
Narrative review
Who was studied
People with BMI ≥30 kg/m2 or BMI ≥27 kg/m2 with excess weight-related conditions
What was measured
Efficacy and safety of obesity medications, weight loss, cardiometabolic risk factors

THE PAPER

Obesity medications: A narrative review of current and emerging agents.

Qi QYD, Cox A, McNeil S, Sumithran P. Osteoarthr Cartil Open, 2024.

PubMed 38737985 ↗DOI 10.5694/mja2.52031 ↗

Heart & arteriesWeight & appetite

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.